Navel G Daver

251PUBLICATIONS
565CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (251)

|Oct 04, 2026
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.

|Sep 18, 2026
Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.

|Aug 13, 2026
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jul 07, 2026
Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Pageof 42

Frequent Collaborators

166 joint publications

Courtney DiNardo

150 joint publications

Tapan M Kadia

124 joint publications

Hagop M Kantarjian

110 joint publications

Nicholas Short